Guillain-Barré syndrome presenting with facial diplegia following COVID-19 vaccination in two patients

Gorande Kanabar,1,2 Phil Wilkinson3

SUMMARY
In March 2020, the WHO declared COVID-19 to be a global pandemic and since December 2020, millions of vaccines have been administered. To date, cases of Guillain-Barré syndrome (GBS) following a COVID vaccine (Pfizer, Johnson & Johnson, Janssen, AstraZeneca) have been reported. A 61-year-old woman developed bilateral asymmetrical lower motor neuron (LMN) facial weakness followed by limb symptoms, 10 days after receiving the first dose of AstraZeneca COVID vaccine. The second patient was a 56-year-old man who, 9 days after receiving first dose of AstraZeneca COVID vaccine, developed bilateral asymmetrical LMN facial weakness with limb symptoms. Intravenous immunoglobulin was administered with rapid recovery. These cases of GBS following the AstraZeneca COVID vaccine add to cohort of patients reported. We flag up to raise awareness of this condition post-COVID-19 vaccine and highlight the prominent bifacial involvement. Early diagnosis and prompt treatment with intravenous immunoglobulin led to rapid recovery.

BACKGROUND
All approved COVID-19 vaccines can cause minor side effects in the population with the most common being sore arm, fatigue and chills.1 There have been some rare blood clotting cases with the AstraZeneca and Janssen vaccines, as well as cases of myocarditis following the Pfizer vaccine. A widespread study of the Pfizer vaccine found that the prevalence of acute side effects was the same in the treatment and control groups, but data since this study indicate that this may have been a biased result.2 Given the dynamic nature of measuring vaccine side effects, this report aims to contribute to the literature by informing practitioners of an additional potential rare side effect.

Recently, the European Medicines Agency (EMA) and Food and Drug Administration (FDA) have listed Guillain-Barré syndrome (GBS) as a side effect of Janssen, AstraZeneca and Johnson & Johnson vaccines.2,3 To date, there have been few case reports of GBS following COVID-19 vaccination reported whereas millions of vaccines have been administered in the UK.4–7 Therefore, the causal link is not yet provable but given the severity of the cases involved, there is a need for awareness among the clinicians about this possible association. There is also no indication that COVID-19 vaccines should stop being administered and we fully support the current WHO recommendations. Our two cases had received AstraZeneca vaccines. It is important that clinicians are aware of this condition occurring post-COVID-19 vaccine, as early diagnosis and treatment with intravenous immunoglobulin (IVIg) can improve clinical outcome as in our cases.

CASE PRESENTATION
Case 1: a 61-year-old woman received the first dose of the AstraZeneca COVID-19 vaccine and, for the following 2 days felt unwell with general malaise. Ten days later, the patient noticed bifacial, left > right, weakness with prominent lower facial involvement. This was accompanied by asymmetrical, left > right, lower limb weakness and tingling in her feet and a day later in her hands. The patient’s facial and limb weakness progressed over the next few days. One week after onset of symptoms, the patient went to the hospital for medical consultation. There was no respiratory involvement.

The patient has a history of multiple sclerosis, diagnosed 15 years ago but she had been asymptomatic since an episode of optic neuritis 11 years ago. She has never been on any disease-modifying treatment.

The patient had bilateral lower motor neuron facial weakness (House-Brackmann grade 4 on the left and grade 3 on the right side), and lower limb weakness (3/5 proximally and 4/5 distally). She also has decreased vibration sensation up to her ankles bilaterally and was areflexic with flexor plantar responses.

Case 2: a 56-year-old man received the first dose of the AstraZeneca COVID-19 vaccine and for 2 days experienced severe ‘flu-like’ symptoms. A week later, the patient developed sudden-onset severe back and lower limb radicular pain followed by waist down numbness and a sensation of heaviness in his legs. The following day, he developed tingling and numbness in his fingertips and weakness (left > right) with tingling and numbness on the face and was admitted to hospital. There were no bladder or bowel symptoms and no respiratory involvement.

On examination, he had bilateral lower motor neuron facial weakness (House-Brackmann grade 4 on the left and grade 3 on the right side) and decreased vibration sensation at the ankles. He was areflexic with flexor plantar responses.

INVESTIGATIONS
Case 1: Cerebrospinal fluid (CSF) was acellular with a protein level of 1.64 g/L. Motor nerve conduction

1Department of Clinical Neurophysiology, East and North Hertfordshire NHS Trust, Stevenage, UK
2Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children, London, UK
3Department of Neurology, East and North Hertfordshire NHS Trust, Stevenage, UK

Correspondence to Dr Gorande Kanabar; gkanabar@nhs.net

Accepted 27 September 2021

© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Kanabar G, Wilkinson P. BMJ Case Rep 2021;14:e244527. doi:10.1136/bcr-2021-244527
studies fulfilled the criteria for demyelinating polyneuropathy (Table 1). Sensory nerve studies were within normal limits. There were no acute denervation potentials on needle electromyogram (EMG) studies.

Case 2: CSF showed a protein level of 1.6 g/L and two lymphocytes only. Motor nerve conduction studies fulfilled the criteria for demyelinating polyneuropathy. Sensory nerve studies were within normal limits (Table 1). There were no acute denervation potentials on needle EMG studies.

All blood tests including serological tests for other causes of peripheral neuropathy were within normal limits/negative in both cases.

TREATMENT AND OUTCOME
Case 1: patient reached level 1 of Brighton criteria for diagnostic certainty of GBS.

The patient received a course of IVIg 0.4 g/kg/day for 5 days. By the third day of IVIg, the patient started to notice improvement in the facial and limb weakness. At 3 weeks, the patient still had mild residual proximal muscle weakness (4/5).

Case 2: patient reached level 1 of Brighton criteria for diagnostic certainty of GBS.

The patient received a course of IVIg 0.4 g/kg/day for 5 days. From the third day of treatment onwards, the patient made a rapid improvement of all his symptoms with complete recovery within 10 days.

DISCUSSION
In December 2019, the first case of SARS-CoV-2 was reported in Wuhan, China. On 11 March 2020, the WHO declared COVID-19 to be a global pandemic. Acute inflammatory demyelinating polyneuropathy (AIDP) type of GBS along with rarer variants such as Miller Fisher syndrome, polynoeritis cranialis, bilateral facial palsy with paraesthesia and isolated oculomotor neuropathy have been reported in association with COVID infection.

However, a multicentre study in Northern Italy by Filosto et al proposes a pathological link as there was increased incidence of GBS during the COVID-19 pandemic; the predominant subtype was AIDP type of GBS. The incidence of GBS is approximately 1.1–1.8 cases per 100 000 people per year but this may vary after exposure to infectious agents known to cause GBS. Triggering pathogens include viruses (eg, Cytomegalovirus, Epstein-Barr virus, Influenza A, Hep E, measles, Zika) and bacteria (eg, Campylobacter jejuni, Mycoplasma pneumoniae and Haemophilus influenzae). Postinfectious and autoimmune pathogenic mechanisms have been described and other associations with immunisation, surgery and malignancy have also been reported.

Both patients described in this report had bilateral facial weakness at presentation. In the literature, facial diplegia is described only in 0.25%–0.8% of all patients with GBS at presentation although facial nerve paralysis may subsequently be seen in 27%–50% of GBS cases. In COVID-19 associated GBS, bilateral facial palsy was described in 20% of cases. The prevalence of GBS in recipients of any vaccine is rare and is reported as 0.07–0.46 cases per 100 000. During the H1N1 pandemic in 2009, an excess case rate of 0.8 cases per million vaccinations was observed. The pathophysiological mechanisms by which vaccination may cause GBS remain uncertain. They are hypothesised to be immune-mediated or autoimmune reactions, which are related to the production of autoreactive antibodies induced by vaccine epitopes. In our two cases, the rapid improvement in symptoms in response to IVIg treatment supports immune-mediated cause. Symptoms of GBS have usually occurred up to 6 weeks after a vaccine dose although some authors suggest the consideration of a longer time frame. Due to a lack of case-controlled data, the Institute of Medicine could not refute nor confirm the causal relationship between GBS and various vaccines.

Recently, the EMA has reported that around 51.4 million doses of Vaxzevria AstraZeneca AB had been given to people in the European Union/European Economic Area by 20 June 2021 and 227 cases of GBS had been reported by 27 June 2021. A few more case reports of GBS following COVID vaccination have been reported lately. Nasuelli et al has reported a case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 vaccine.

The two patients we report here were of similar ages and presented within 1 week of each other, this may be a result of the age-specific vaccination scheme in the UK.
Given that millions of vaccinations have been administered this does not imply any strong causality between COVID-19 vaccines and GBS, nor does it suggest that vaccinations should be halted. However, the epidemiology of this disease and any vaccination side-effects are still emerging and so we should remain alert to address these issues.\(^{14}\)

We report these cases in order to raise the awareness of GBS occurring post-COVID-19 vaccine as early diagnosis and prompt treatment with IVIg can rapidly reduce morbidity as shown in our cases. However, we reiterate that association does not imply causation itself and therefore we require more observed cases and a natural experiment study to determine the possibility of causality.

### Learning points

- Guillain-Barré syndrome (GBS) can present following COVID-19 vaccination. The patients described add to the cohort of patients with GBS reported after AstraZeneca vaccination. These observations raise the question about casual relationship between the two facts about which healthcare professional should be aware.
- Lower motor neuron facial weakness can present as GBS following COVID-19 vaccination.
- Early diagnosis and prompt treatment with intravenous immunoglobulin as in our cases lead to rapid recovery.

### Acknowledgements

We are grateful to Dr VP Misra, Consultant Neurophysiologist for his assistance with this report.

### Contributors

GK contributed towards writing the summary, figure, case 2, discussion and references. PW contributed towards writing case 1.

### Funding

The authors have not declared a specific grant for this research from any profit sectors.

### Competing interests

None declared.

### Patient consent for publication

Consent obtained directly from patient(s).

### Provenance and peer review

Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

### REFERENCES

1. National Health Service Guidance, Coronavirus (COVID-19) vaccines side effects and safety, 2021. Available: https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/safety-and-side-effects/
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15.
3. COVID-19 vaccine safety update VAXZEVRIA AstraZeneca ab. Available: https://www.eea.europa.eu/en/documents/covid-19-vaccine-safety-update-covid-19-vaccine-safety-update-vaxzervia-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf
4. COVID-19 vaccine janssen: guillain-barre syndrome listed as a very rare side effect. Available: https://www.eea.europa.eu/en/news/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect
5. Dyer O. Covid-19: regulators warn that rare guillain-barre cases may link to J&J and astrazeneca vaccines. BMJ 2021;374. doi:10.1136/bmj.n1786
6. Nasuelli NA, De Marchi E, Cecchin M, et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neuro Sci 2021;17:1–3.
7. Hasan T, Khan M, Khan S, et al. Case of guillain-barré syndrome following COVID-19 vaccine. BMJ Case Rep 2021;14:e243629.
8. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of guillain-barré syndrome and validation of Brighton criteria. Brain 2014;137:33–43.
9. Maury A, Lyoubi A, Pfeffer-Smadja N, et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol 2021;177:51–64.
10. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021;268:1133–70.
11. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol 2021;268:3059–71.
12. Keddie S, Pakpour J, Mousse C, et al. Epidemiological and cohort study finds no association between COVID-19 and guillain-barré syndrome. Brain 2021;144:168–92.
13. Lunn MF, Cornblath DR, Jacobs BC, et al. COVID-19 vaccine and guillain-barré syndrome: let’s not leap to associations. Brain 2021;144:357–60.
14. Filosto M, Cotti Piccinelli S, Gazzina S. Guillain-barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 2020;IV:150–6.
15. Lowe J, Pfaff J. The ultimate poker face: a case report of facial diplegia, a guillain-barré variant. Clin Pract Cases Emerg Med 2020;IV:150–3.
16. Wakeley BR, Yuki N. Isolated facial diplegia in guillain-barré syndrome: bifacial weakness with paresthesias. Muscle Nerve 2015;52:927–32.
17. Wang D, Bolze D, McElhaney J. No evidence of a link between influenza vaccines and guillain–barre syndrome–associated anti-ganglioside antibodies. *Influenza and6 journal 2012;6:159–66.
18. D’alo GL, Zorzi E, Capanna A, et al. Frequently asked questions on seven rare side effect. *J Prev Med Hyg 2017;58:E13–26.
19. Waheed S, Bayas A, Hind E, et al. Neurological complications of COVID-19: guillain- barre syndrome following Pfizer COVID-19 vaccine. Cureus 2021;13:e13426.
20. George J. Senior staff write guillain-barré after COVID-19 vaccine: case report - clinical trial participant recovered after IVIG treatment. MedPage Today, 2021.

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service

If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.

Kanabar G, Wilkinson P. BMJ Case Rep 2021;14:e244527. doi:10.1136/bcr-2021-244527